Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian F. Smith, CEO. “Our Phase 1/2 and open-label extension studies have provided a strong foundational understanding of zorevunersen and support the EMPEROR Phase 3 registrational study design. We continue to generate long-term data that are helping us appreciate the disease modifying potential of zorevunersen. At the same time, we see growing awareness of Dravet syndrome as a severe neurodevelopmental disease, which is bringing attention to our work and a high degree of interest in zorevunersen.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
- Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
- STOK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Stoke Therapeutics initiated with a Buy at Jefferies
- Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome